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1  | INTRODUC TION
Although human papillomavirus (HPV) is the most important ae-
tiological agent of initiation of cervical intraepithelial abnormal-
ities, the majority of infections resolve spontaneously and do not 
confer progression to disease. Studies have reported an associa-
tion of single nucleotide polymorphisms (SNPs) within cytokine 
genes with cell clearance from HPV viral infection (Fong, Siddiqui, 
& Mark, 1994) as well as susceptibility to a higher risk of human ma-
lignant tumours (Eskdale et al., 1998; Nunobiki et al., 2011; Ueda 
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Cervical cancer (CCa) is one of the most common malign diseases in women associ-
ated with human papillomavirus (HPV). The virus is an initiating factor, but not suf-
ficient for the development of cervical intraepithelial lesions (CIN) and CCa. The 
disease might be a result of the influence of host's genetic factors and polymor-
phisms in inflammatory-related genes that modify the immune response to HPV and 
attribute to cancer susceptibility. We carried out a study to determine the associa-
tion between TNF-a-238G/A and TNF-a-308 G/T polymorphisms with HPV-positive 
CIN and CCa in women living in the Republic of North Macedonia. Using multiplex 
SNaPshot analysis for single nucleotide polymorphisms (SNPs), we analysed the gen-
otype and allele distributions of TNF-a-238G/A and TNF-a-308 G/T in 134 cases 
(HPV-positive and histologically confirmed CIN and CCa) and in 113 controls (cyto-
logical and HPV-negative women). For further analysis, the case group was stratified 
in three subgroups (all cases: CINs+ CCa− group; CIN2+ -group and CIN1− group). 
Data analysed using the odds ratio (OR) and chi-square test showed the frequency 
of AA genotypes and A alleles are not significantly higher in cases compared to the 
controls for both SNPs: AA of TNF-a-238 (0.7% versus 0%) and TNF-a-308 (1.5% 
versus 0.9%) as well as A allelic frequency (3.0% versus 1.7%) and (13.1% versus 10.6), 
respectively. The comparison of the case's subgroups with the control group did not 
show a statistically significant difference. Compared to controls, TNF-a-238G/A and 
TNF-a-308 G/T are not associated with the risk of HPV associated CIN or CCa in the 
studied women.
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et al., 2003). Cytokines molecules are involved in the fighting of 
an organism against viral infections and could influence the HPV 
persistence and cervical intraepithelial neoplasia (CIN) progression 
changing the immune response to HPV and modifying the risk for 
CCa. Tumour necrotizing factor (TNF-a) is an important pro-inflam-
matory cytokine involved in host immune defence from different 
pathogens including the HPV infection, its beneficial role, but it 
could be also harmful when its systemic higher production lead to 
autoimmune or malign diseases (Hajeer & Hutchinson, 2001). Two 
SNPs in this gene (rs361525 and rs1800629) could influence the 
CCa susceptibility based on finding that they can modulate TNF-a 
expression: rs1800629 A allele tends increasing and rs361525 A 
allele lowering the TNF-a expression (Fong et al., 1994; Kroeger, 
Carville, & Abraham, 1997; Wilson, Symons, McDowell, McDevitt, 
& Duff, 1997).
A number of studies investigated the association of these poly-
morphisms with different cancers, including cervical cancer (Li, Liu, 
Liu, & Lu, 2018; Roszak, Misztal, Sowinska, & Jagodzinski, 2015), and 
their implication in control of HPV infection and inhibition of E6/
E7 transcription in keratinocytes infected with HPV 16 and HPV 18 
(Kyo et al., 1994; Soto, Das, Lengert, Finzer, & zur Hausen, & Rosl, 
1999) as well. So far, many such studies reported contradictory or 
ambiguous results. The exact mechanism that could affect suscep-
tibility to CIN and CCa is still unknown. It could be possible that dif-
ferent mechanisms influence this process.
We conducted a case–control study to find out whether 
rs361525 and rs1800629 gene promoter polymorphisms are asso-
ciated with HPV-positive CIN and CCa. Referring to the previous 
finding revealing that HPV persistent infection is the main risk for 
cervical lesion development; in this study, we included only HPV-
positive and histologically confirmed CINs and CCa. To the best of 
our knowledge, still, no report is available addressing the association 
of these SNPs in the TNF-α promoter with the susceptibility to HPV 
associated CIN and CCa in women living in the Republic of North 
Macedonia.
2  | MATERIAL AND METHODS
2.1 | Study subjects
The study was performed on 113 healthy controls (HPV and cy-
tological negative women) which underwent routine screening 
for cervical cancer (HPV testing combined with cervical cytology) 
and 134 patients (HPV-positive and histological CIN or CCa con-
firmed women) that were recruited in the Clinic for Gynecology and 
Obstetrics, Skopje for further examination.
All the samples were collected from the women living in the 
Republic of North Macedonia. The cytological and/or histological 
status was confirmed by pathological diagnosis on cervical swabs and 
surgical specimens, respectively. The cytological diagnosis was done 
by cytologists using the Bethesda classification system. Histology 
was performed on specimens collected by a colposcopy-directed 
biopsy and/or cone specimens collected by loop excision procedure 
in patients where it was indicated or on surgical specimens. HPV 
DNA and SNP typing were performed on DNA isolated from cervical 
swabs, in the Laboratory for Virology and Molecular Diagnostics of 
the Institute of Public Health of the Republic of North Macedonia 
(IPHRNM) and the Research Center for Genetic Engineering and 
Biotechnology (RCGIB), Academy of Sciences and Arts of Republic 
of North Macedonia (MASA).
Clinical data were collected from the medical records of pa-
tients admitted in the Clinic for Gynecology and Obstetrics, 
Skopje. The average age of the patients (40 CIN1, 57 CIN2/3, 37 
CCa) was 46.38 (±11.42 years' deviation from the mean). Control 
cases had a mean age of 46.11 years ± 9.41 years. Eligible control 
had no history of HPV and CIN. Written informed consent and 
a fulfilled questionnaire were obtained from all patients and the 
control women. All participants were voluntarily involved in this 
research.
The study protocol was approved by the Ethics Committee of the 
Institute of Public Health of the Republic of North Macedonia fol-
lowing the tenets of the Helsinki Declaration and national guidelines 
for medical research.
2.2 | DNA isolation
QIAamp DNA Blood Mini Kit was used for DNA extraction from cer-
vical swabs according to the manufacturer's instructions.
2.3 | HPV testing
Human papillomavirus testing was performed using HPV4ACE 
screening, Seeplex, Seegene, Korea. HPV-positive and not geno-
typed cases were additionally analysed with PCR method based on 
the amplification of the viral L1 region using MY09/11 consensus 
degenerate primers (Bernard et al., 1994).
2.4 | SNP genotyping
Single nucleotide polymorphisms Genotyping was performed using 
a multiplex polymerase chain reaction (PCR) followed by single-
nucleotide primer extension assay test. The primers that were used 
in both analyses were designed using the primer design software—
Primer3Plus (http://www.bioin forma tics.nl/cgi-bin/prime r3plu s/
prime r3plus.cgi). Secondary structures and potential primer dimers 
were predicted using the PriDimerCheck (http://bioco mpute.bmi.
ac.cn/MPpri mer/primer_dimer.html). The primers sequences are 
shown in Table 1. The PCR multiplex reaction was performed in 25 μl 
final volumes, and the mix contained 1× Reaction Buffer, 200 μM of 
dNTPs, 2 mM of MgCl2, 2U of AmpliTaq Gold polymerase (Applied 
Biosystems) and 10 ng of genomic DNA. Cycling conditions were 
as follows: 10 min at 95°C, followed by 35 cycles of 1 min at 95°C, 
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1 min and 15 s at 59°C, 2 min at 72°C and a final extension at 72°C 
for 10 min.
Before the single base extension reaction, an aliquot of 1 μl 
of the PCR product was treated with 0.5 μl of ExoSAP-IT (USB 
Corporation) for 60 min at 37°C to eliminate unincorporated nu-
cleotide triphosphates and excess PCR primers. The enzymes were 
inactivated at 86°C for 20 min. Multiplex single base extension reac-
tion was performed in 5 μl final volume, combining 2 μl of SNaPshot 
ready reaction mix (Applied Biosystems), 2 μl of the purified PCR 
product and 1 μl of the mutation-specific primer cocktail. The mu-
tation-specific primer primers were 5′ tailed with a poly C sequence 
to produce extension products with 24 and 44 nucleotides long to 
allow separation by capillary electrophoresis. The cycling conditions 
were 10 s at 96°C, 10 s at 50°C and 30 s at 60°C, for 25 cycles. To 
remove unincorporated ddNTPs, the final products were incubated 
with 1 U of shrimp alkaline phosphatase (SAP) (USB Corporation) for 
1 hr at 37°C, followed by 15 min at 85°C to inactivate the enzyme. 
The 1 µl of the SAP-inactivated single-nucleotide extension reaction 
was diluted with 12 µl Hi-Di Formamide (Life Technologies) and sup-
plied with 0.5 µl GeneScan 120 LIZ Size Standard (Life Technologies). 
The mixture was denatured at 95°C for 5 min and loaded onto an ABI 
PRISM 3,130 Genetic Analyzer (Life Technologies). Capillary electro-
phoresis was performed following the manufacturer's instructions. 
Extension products were visualized and analysed using GeneScan 
4.0 (Life Technologies). Initial validation of the method was per-
formed against the DNA sequencing of the amplified regions.
2.5 | Statistical analysis
The association between polymorphisms and the stage of cervical le-
sions was assessed using the Pearson chi-square test and the Fisher 
exact test, where indicated. A probability level of less than 0.05 was 
considered as statistically significant. An estimation of odds ratio 
(OR) and 95% confidence interval (CI) for each allele and gene were 
performed. GG genotype was used as a reference genotype for both 
TA B L E  1   Primers used in multiplex and for single-nucleotide primer extension reaction in detection of rs361525 and rs1800629
SNPbp** PCR (bp) P* 5′−3′ bp SNP E**
rs361525 F GCCCCTCCCAGTTCTAGTTC 244
R AAAGTTGGGGACACACAAGC
SNP AGA AGA CCC CCC TCG GAA TC + 4 (poly 
C tail)
 F C/T 24.7/25.3
rs1800629 F ACCTGGTCCCCAAAAGAAAT 175
R GCTTGTGTGTCCCCAACTTT
SNP GCAATAGGTTTTGAGGGGCATG + 22 (poly 
C tail)
 F C/T 45.9/46.3
Note: *Primer orientation F (forward), R (reverse).
Abbreviations: bp, base pairs of PCR product; E**, Electrophorogram position (referent/variant); P*, Primer orientation.
TA B L E  2   Clinical and demographic characteristic of study group (age, histological results and HPV type presence)
Characteristic N patients (%) N controls (%)
Age
<35 21 (15.7) 19 (16.8)
≥35 113(84.3) 94 (83.2)
Tobacco smokers 102 (76.1) 85 (75.2)




Cervical cancer 37 (27.6)
Total 134 (100%) 113 (100%)
HPV type CIN1 (%) CN2/3, CCa (%) Total
HPV 16 and/or 18 6 (15.0) 58 (61.7) 64 (47.8)
Other high risk HPV types 
(31,33,39,42,45,52,51,58…..)
24 (60.0) 20 (21.3) 44 (32.8)
Multiple infections 10 (25.0) 16 (17.0) 26 (19.4)
Total 40 (100.0) 94 (100.0) 134 (100.0)
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rs361525 and rs1800629. The alleles in the control group were ana-
lysed for Hardy–Weinberg equilibrium using a chi-square test with 
SISA statistics available at http://www.quant itati veski lls.com/sisa/
stati stics/ twoby2.htm. The haplotype analyses were done using 
SHEsis software (http://www.analy sis.bio-x.cn/myAna lysis.php).
3  | RESULTS
This study was performed on 247 women that were analysed for 
rs1800629 and rs361525 polymorphisms. The demographic and 
clinical characteristics of the case and the control group are pre-
sented in Table 2. The allelic and genotype frequencies of the SNPs 
in the cases stratified in three groups and the control group are sum-
marized in Tables 3 and 4 and included the results of the chi-squared 
tests performed to detect any association between the two SNPs 
and the development of precancerous lesions or cervical cancer. 
The large p values varying between 0.1 and 0.5 indicated no statisti-
cally significant differences between the case and the control group 
for both SNPs tested. The alleles in the control group were within 
Hardy–Weinberg equilibrium.
The lack of association between analysed SNPs and HPV asso-
ciated cervical lesions cancer and cervical cancers were in addition 
confirmed by the large p values obtained on genotype-based analy-
sis as well as on the dominant and recessive model analysis.
Both comparisons did not find statistically significant differ-
ences between all the case groups and the control group. It should 
be noted that we could not test the recessive model in case of SNP 
rs1800629 due to lack of women with AA genotype in the control 
group.
Regarding HPV type distribution, HPV 16 and HPV 18 were con-
firmed as more frequent in higher grade precancerous lesions and 
CCa compared to CIN1 (Pearson's = 26.5, p = 0).
The statistical analysis concluded that the analysed polymor-
phisms cannot be associated with the development of precancerous 
lesions or cervical cancer with statistical significance. Haplotype 
analysis also did not show a significant difference between SNPs in 
the case group (collectively and divided into subgroups) and the con-
trol group (Table 5).
4  | DISCUSSION
Tumour necrosis factor-alpha (TNF-α) is a potential pro-inflamma-
tory cytokine that plays a critical role in a wide range of inflamma-
tory, autoimmune and malignant diseases (Bazzoni & Beutler, 1996; 
Beutler & Bazzoni, 1998). Its function in the immune response has 
been implicated in the development of cancer (Dranoff, 2004) 
mainly through induction of proliferation, invasion and metastasis 
of tumour cells (Roszak, Misztal, Sowinska, & Jagodzinski, 2015). A 
study has confirmed a pivotal role of TNF-α in tumour promotion 
(Moore, O'Garra, de Waal Malefyt, Vieira, & Mosmann, 1993). High 
levels of serum TNF-a were detected in CCa patients with bed prog-
nosis (Chopra, Dinh, & Hannigan, 1998).
The role of TNF-α in innate immunity and malign pathology is 
challenging to investigate due to its genetic characteristics that are 
reflected through regulating its production. TNF-a SNPs 238G/A and 
308G/A were most frequently analysed polymorphisms as CCa sus-
ceptibility markers.
Our study is based on the hypothesis that A allele at rs361525 
allele has a protective effect and the same allele at rs1800629 is 
associated with the susceptibility to develop cervical cancer (Pan 
et al., 2012). The results failed to confirm this hypothesis.
However, the results regarding the genotype frequency of AA/
GA at rs361525 and rs1800629 (5.2% with 24.5%, respectively) in 
HPV-positive CIN and CCa women in our study are in accordance 
TA B L E  3   Allele and genotype frequency of rs361525 in cases and controls
rs361525 G1n (%) G2 n (%) G3 n (%) controls n (%) P1 P2 P3 P4
Allele
A 8 (3.0) 8 (4.2) 0 4 (1.7) 0.5* 0.15* 0.57* 0.1*
G 260 (97.0) 180(95.8) 80(100) 222 (98.2)
Genotype
AA 1 (0.7) 1(1.0) 0 0 1* 0.4* 1* 1
GA 6 (4.5) 6(6.4) 0 4 (3.5) 0.75* 0.35* 0.57* 0.1
GG 127(94.8) 87(92.6) 40(100) 109 (96.5) Ref Ref Ref
a AG/AA versus 
GG
7 (5.2) 7 (7.4) 0 4 (3.5) 0.75* 0.2 0.57 0.1*
b AA versus AG/
GG
133(99.3) 93(99.0) 40 (100) 113(100) 1* 0.45 1 1
n-total 134(100) 94 (100) 40 (100) 113 (100) – – – –
Note: p1 = G1 (all cases)/controls; p2 = G2 (CIN2/3 + Cca)/controls; p3 = G3 (CIN1)/controls; p4 = G3/G2
aRecessive model. 
bDominant model. 
*p value calculated by Fisher exact test. 
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with the results obtained in same case group from other different 
geographical populations such as the USA (Hispanic women: 6% and 
25%; Nonhispanic: 8% and 29%) (Deshpande et al., 2005); UK: 6% 
and 25%; (Kirkpatrick et al., 2004) and India: 2% and 24% (Kohaar 
et al., 2007). A slightly lower frequency of AA/GA for rs361525 may 
be noted for women in North Macedonia compared to the women in 
the USA and UK and slightly higher than Indian women. After com-
paring the rs361525 and rs1800629 genotype frequencies from our 
study to previously reported frequencies by other authors within the 
same geographical region (Pavkovic et al., 2017;Trajkov et al., 2009), 
a small difference is found in rs361525: AA/AG (8.5%), that may 
be explained with the larger control group used in the other study 
that consisted of 310 individuals including male individuals, com-
pared to 113 women controls in this study. The AA/GA genotype 
frequencies of rs1800629 are found to be comparable (20.8%) 
(Pavkovic et al., 2017) (Table 6).
A number of studies conducted in the previous years, analyzing 
the association of rs361525 and rs1800629 with development of 
cervical cancer, failed to establish a statistically significant relation-
ship, and the results were inconclusive and contradictory (Calhoun 
et al., 2002; Deshpande et al., 2005; Duarte et al., 2005; Gostout 
et al., 2003; Govan, Constant, Hoffman, & Williamson, 2006; 
Ivansson, Magnusson, Magnusson, Erlich, & Gyllensten, 2008; 
Jang et al., 2001; Kohaar et al., 2007; Singh, Jain, Sachan, & 
Mittal, 2009; Stanczuk, Sibanda, Tswana, & Bergstrom, 2003; 
Wang, Zhang, Walayat, Chen, & Wang, 2011; Zhou et al., 2011). 
The differences in the results may be partially attributed to differ-
ences of factor such as sample size, inadequate statistical power 
TA B L E  4   Allele and genotype frequency of rs1800629 in cases and controls
rs1800629 G1 n (%) G2 n (%) G3 n (%) controls n (%) P1 P2 P3 P4
Allele
A 35 (13.1) 24 (12.8) 11 (13.8) 24 (10.6) 0.4 0.5 0.5 0.8
G 233 (86.9) 164(87.2) 69 (86.2) 202 (89.4)
Genotype
AA 2 (1.5) 1 (1.1) 1 (2.5) 1 (0.9) 1* 1* .4* .5*
GA 31 (23.1) 22 (23.4) 9 (22.5) 22 (19.5) 0.5 0.5 0.6 1
GG 101 (75.4) 71 (75.5) 30 (75.0) 90 (79.6) Ref Ref Ref Ref
AG/AA versus GGa  33 (24.6) 23 (24.5) 10 (25.0) 23 (20.4) 0.36 0.47 0.6 1
AA versus AG/GGb  142 (98.5) 93 (98.9) 39 (97.5) 112 (99.1) 1* 0.59 0.1* 0.5
n-total 134 (100) 94 (100) 40 (100) 113 (100) – – – –
Note: p1 = G1 (all cases)/controls; p2 = G2 (CIN2/3 + Cca)/controls; p3 = G3 (CIN1)/controls; p4 = G3/G2
aRecessive model. 
bDominant model. 
*p value calculated by Fisher exact test. 
TA B L E  5   The association between TNF-a haplotypes and CIN/CCa
rs361525/rs1800629 Cases(freq) Control (freq) Chi2 FisherP OR 95% CI
AG* 7.02 (0.037) 4.00 (0.018) 1.55 0.21 2.16 0.62 7.50
GA* 23.02 (0.122) 24.00 (0.106) 0.29 0.59 1.18 0.64 2.16
GG* 156.98 (0.835) 198.00 (0.876) 1.14 0.28 0.74 0.42 1.28
AA 0.98 (0.005) 0.00 (0.000)
TA B L E  6   Distribution (%) of rs361525 and rs1800629 genotypes in HPV-positive CIN and CCa women among different population
Region
rs361525 genotypes n (%) rs1800629 genotypes n (%)
Ass. studyGG% AA/GA% GG% AA/GA%
USA hispanic 119 (94) 7 (6) 86 (75) 29 (25) No Deshpande et al., 2005
USA nonhispanic 167 (92) 15 (8) 102(71) 41 (29) No Deshpande et al., 2005
UK 79 (94) 5 (6) 63 (75) 21 (25) No Kirkpatrick et al., 2004
India 132 (98) 3 (2) 103 (76) 32 (24) Yes* Kohaar et al., 2007
North Macedonia 127 (94.8) 7 (5.2) 101 (75.5) 23 (24.5) No Present study
Abbreviations: Ass., association; h*, hispanic; n*, nonhispanic; Yes*, there is confirmed association only for rs1800629.
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of the studies, racial and ethnic differences, publication bias or 
uncorrected multiple hypothesis testing. Some additional factors 
may also influence the difference in susceptibility to CCa regard-
ing this polymorphism such as contraceptive usage, time of first in-
tercourse, living environment and habits, economic conditions and 
psychological factors. Future studies should take these additional 
factors into consideration. The difference in results may also be 
attributed to gene–gene interactions and the evidence that TNF-
α is part of the MHC class III cluster. The individual variations in 
TNF-α production are related to the whole haplotype rather than 
to the effect of individual TNF-α alleles (Abraham et al., 1993). 
This finding may suggest future studies should avoid looking into 
the TNF-α as an isolated gene. Regarding the HPV types distri-
bution, the results are in accordance with many previous studies 
(Bergeron et al., 1992; Duvlis et al., 2002) but this study cannot 
clarify the mechanism of HPV type influence on TNF-a SNP geno-
type association with CIN and CCa.
This study provided valuable data about the allele and genotype 
frequencies of this variant in women with CIN and cervical cancer 
living in Republic of North Macedonia.
5  | CONCLUSION
According to our knowledge, this study reports the initial TNF-α 
rs361525 and rs1800629 polymorphisms results in CINs and the 
cervical cancer women from the Republic of North Macedonia. The 
genetic testing of these polymorphisms for individual susceptibility 
to HPV infection and CCa failed to confirm the association between 
these variants and cervical carcinogenesis in the examined women. 
To clarify the pathogenesis of HPV induced cervical lesions and cer-
vical cancer, a meta-analysis of different cytokines may be required 
and the influence of additional factors should be considered.
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